Luchsinger I, Knöpfel N, Theiler M, et al. - In this case series, researchers sought to assess the clinical response of Netherton syndrome (NS), a severe and difficult-to-treat genetic condition with high disease burden, to treatment with the interleukin 17 (IL-17) antagonist secukinumab. From December 1, 2018, to December 1, 2019, they shared their experience of compassionate use therapy with secukinumab in 4 patients (age range, 9-27 years; 3 male and 1 female) with severe NS, including 2 children, with 3 patients still undergoing treatment at the time of final analysis. This initial case series reporting the use of anti–IL-17 therapy in NS showed marked cutaneous improvement, especially in 2 pediatric patients with erythrodermic phenotypes. No severe adverse events have been identified.